474 related articles for article (PubMed ID: 17296794)
1. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations.
Detmer SA; Chan DC
J Cell Biol; 2007 Feb; 176(4):405-14. PubMed ID: 17296794
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A.
Franco A; Dang X; Zhang L; Molinoff PB; Dorn GW
J Pharmacol Exp Ther; 2022 Nov; 383(2):137-148. PubMed ID: 36507849
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations.
Amiott EA; Lott P; Soto J; Kang PB; McCaffery JM; DiMauro S; Abel ED; Flanigan KM; Lawson VH; Shaw JM
Exp Neurol; 2008 May; 211(1):115-27. PubMed ID: 18316077
[TBL] [Abstract][Full Text] [Related]
4. Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model.
Zhou Y; Carmona S; Muhammad AKMG; Bell S; Landeros J; Vazquez M; Ho R; Franco A; Lu B; Dorn GW; Wang S; Lutz CM; Baloh RH
J Clin Invest; 2019 Mar; 129(4):1756-1771. PubMed ID: 30882371
[TBL] [Abstract][Full Text] [Related]
5. Mitofusin 1 overexpression rescues the abnormal mitochondrial dynamics caused by the Mitofusin 2 K357T mutation in vitro.
Stavropoulos F; Georgiou E; Schiza N; Bell S; Baloh RH; Kleopa KA; Sargiannidou I
J Peripher Nerv Syst; 2023 Sep; 28(3):329-340. PubMed ID: 37220142
[TBL] [Abstract][Full Text] [Related]
6. Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A.
Franco A; Dang X; Walton EK; Ho JN; Zablocka B; Ly C; Miller TM; Baloh RH; Shy ME; Yoo AS; Dorn GW
Elife; 2020 Oct; 9():. PubMed ID: 33074106
[TBL] [Abstract][Full Text] [Related]
7. Mitofusin 2 gene mutation (R94Q) causing severe early-onset axonal polyneuropathy (CMT2A).
Neusch C; Senderek J; Eggermann T; Elolff E; Bähr M; Schneider-Gold C
Eur J Neurol; 2007 May; 14(5):575-7. PubMed ID: 17437620
[TBL] [Abstract][Full Text] [Related]
8. Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A.
Cartoni R; Martinou JC
Exp Neurol; 2009 Aug; 218(2):268-73. PubMed ID: 19427854
[TBL] [Abstract][Full Text] [Related]
9. Bioenergetic defect associated with mKATP channel opening in a mouse model carrying a mitofusin 2 mutation.
Guillet V; Gueguen N; Cartoni R; Chevrollier A; Desquiret V; Angebault C; Amati-Bonneau P; Procaccio V; Bonneau D; Martinou JC; Reynier P
FASEB J; 2011 May; 25(5):1618-27. PubMed ID: 21285398
[TBL] [Abstract][Full Text] [Related]
10. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development.
Chen H; Detmer SA; Ewald AJ; Griffin EE; Fraser SE; Chan DC
J Cell Biol; 2003 Jan; 160(2):189-200. PubMed ID: 12527753
[TBL] [Abstract][Full Text] [Related]
11. Structural insights of human mitofusin-2 into mitochondrial fusion and CMT2A onset.
Li YJ; Cao YL; Feng JX; Qi Y; Meng S; Yang JF; Zhong YT; Kang S; Chen X; Lan L; Luo L; Yu B; Chen S; Chan DC; Hu J; Gao S
Nat Commun; 2019 Oct; 10(1):4914. PubMed ID: 31664033
[TBL] [Abstract][Full Text] [Related]
12. Finding a new balance to cure Charcot-Marie-Tooth 2A.
Iwata K; Scorrano L
J Clin Invest; 2019 Mar; 129(4):1533-1535. PubMed ID: 30882369
[TBL] [Abstract][Full Text] [Related]
13. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.
Rocha AG; Franco A; Krezel AM; Rumsey JM; Alberti JM; Knight WC; Biris N; Zacharioudakis E; Janetka JW; Baloh RH; Kitsis RN; Mochly-Rosen D; Townsend RR; Gavathiotis E; Dorn GW
Science; 2018 Apr; 360(6386):336-341. PubMed ID: 29674596
[TBL] [Abstract][Full Text] [Related]
14. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene.
Lawson VH; Graham BV; Flanigan KM
Neurology; 2005 Jul; 65(2):197-204. PubMed ID: 16043786
[TBL] [Abstract][Full Text] [Related]
15. A mutation associated with CMT2A neuropathy causes defects in Fzo1 GTP hydrolysis, ubiquitylation, and protein turnover.
Amiott EA; Cohen MM; Saint-Georges Y; Weissman AM; Shaw JM
Mol Biol Cell; 2009 Dec; 20(23):5026-35. PubMed ID: 19812251
[TBL] [Abstract][Full Text] [Related]
16. Mitofusin 2 expression dominates over mitofusin 1 exclusively in mouse dorsal root ganglia - a possible explanation for peripheral nervous system involvement in Charcot-Marie-Tooth 2A.
Kawalec M; Zabłocka B; Kabzińska D; Neska J; Beręsewicz M
Folia Neuropathol; 2014; 52(4):436-42. PubMed ID: 25574749
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the mitofusin 2 R94W mutation in a knock-in mouse model.
Strickland AV; Rebelo AP; Zhang F; Price J; Bolon B; Silva JP; Wen R; Züchner S
J Peripher Nerv Syst; 2014 Jun; 19(2):152-64. PubMed ID: 24862862
[TBL] [Abstract][Full Text] [Related]
18. A cohort study of Han Chinese MFN2-related Charcot-Marie-Tooth 2A.
Lv H; Wang L; Zhang W; Wang Z; Zuo Y; Liu J; Yuan Y
J Neurol Sci; 2015 Nov; 358(1-2):153-7. PubMed ID: 26382835
[TBL] [Abstract][Full Text] [Related]
19. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex.
Misko A; Jiang S; Wegorzewska I; Milbrandt J; Baloh RH
J Neurosci; 2010 Mar; 30(12):4232-40. PubMed ID: 20335458
[TBL] [Abstract][Full Text] [Related]
20. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.
Baloh RH; Schmidt RE; Pestronk A; Milbrandt J
J Neurosci; 2007 Jan; 27(2):422-30. PubMed ID: 17215403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
